interleukin

(redirected from Interleukin-17)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Interleukin-17: IL-17F

in·ter·leu·kin

 (ĭn′tər-lo͞o′kĭn)
n.
Any of various small proteins that are produced by a variety of cell types, especially T cells and other white blood cells, and that regulate many aspects of inflammation and the immune response, including stimulating the production of white blood cells and platelets.

interleukin

(ˌɪntəˈluːkɪn)
n
(Biochemistry) a substance extracted from white blood cells that stimulates their activity against infection and may be used to combat some forms of cancer

in•ter•leu•kin

(ˈɪn tərˌlu kɪn)
n.
any of a family of small proteins that participate in the body's defense system, esp. by promoting the growth and activation of white blood cells.
[1979; inter- + leuk (ocyte) + -in1; so called because such proteins act as agents of communication between different populations of leukocytes]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.interleukin - any of several lymphokines that promote macrophages and killer T cells and B cells and other components of the immune system
lymphokine - a cytokine secreted by helper T cells in response to stimulation by antigens and that acts on other cells of the immune system (as by activating macrophages)
References in periodicals archive ?
GENEVA -- Psoriasis patients switched to ixekizumab after previous exposure to another interleukin-17 inhibitor respond as well as those who are IL-17 antagonist naive, Kim A.
In turn, the high number of TH17 cells led to an increase in the levels of a pro-inflammatory molecule called plasma interleukin-17 (IL-17).
Th17 cells can produce interleukin-17 (IL-17) and play a pro-inflammatory role that has been linked to pregnancy failure.
The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications.
In February 2017, the US Food and Drug Administration approved the Biologics License Application for Siliq, a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor A and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor.
This treatment, part of a class of medicines called interleukin-17 (IL-17) inhibitors, is the first of its kind to be recommended by NICE.
Levels of interleukin-17 in patients with periodontal disease).
The granted claims cover the use of these cell populations to reduce levels of inflammatory cytokines TNF-alpha, interleukin-6, and interleukin-17, all established mediators of inflammatory arthritis in rheumatic diseases.
This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast).
self-antibodies in previously healthy adults presenting with severe Mycobacterial infections (4) or antibodies to interleukin-17 (IL-17) and IL-22 that are associated with chronic candidiasis (5) this group of autoantibodies are now recognized as phenocopies or acquire immune disorders resembling primary genetic immunodeficiency diseases (6).
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.